PM360
NOVEMBER 29, 2022
Traditionally, Medical Affairs has focused on cross-functional collaboration with commercial and R&D teams, medical communication, evidence generation, and dissemination. 1 And, on average , the FDA approved 60% more drugs between 2010-2019 than the yearly average over the previous decade. But that’s just the beginning.
Pharmaceutical Technology
NOVEMBER 3, 2022
Cardiovascular medicines were ranked as the sixth most affected drug class by shortages, as per a 2019 European Association of Hospital Pharmacists (EAHP) survey, says the organisation’s director of finance, Nenad Miljkovi?. To me, even [if] a shortage has resolved, it is only a matter of time until it happens again,” he explains.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
MAY 2, 2023
In 2019, the pharmaceutical industry spent $83 billion on R&D, which is about 10 times what the industry spent per year in the 1980s, 4 yet the average duration to develop a new medicine is still around 10-15 years. About the authors Dr Nils Eckardt joined BeiGene in February 2019 as Vice President, Medical Affairs, Europe.
European Pharmaceutical Review
FEBRUARY 22, 2023
Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics. 8 Future potential Celltrion sees potential for the platform to be applicable to other biologics, according to SungHyun Kim, Head of the company’s Medical Science Division. 2019 [cited 2023Feb].
Veeva
FEBRUARY 6, 2022
According to Veeva Pulse data , COVID-19 has accelerated the shift to digital for life sciences, with significant growth in remote and digital engagement since early 2020, and a 10X increase of HCPs using three or more channels in their engagement with pharma 1. Veeva Pulse analysis. Across Health and Veeva: Intelligent HCP Engagement.
Expert insights. Personalized for you.
95 
Let's personalize your content